The REMEDEE trial: 5-Year results on a novel combined sirolimus-eluting and endothelial progenitor cells capturing stent

Keyphrases

• Sirolimus 100%
• Stent 100%
• Endothelial Progenitor Cell Capture 100%
• 5-year Outcomes 100%
• Taxus 75%
• Stent Thrombosis 50%
• 5-year Follow-up 50%
• Myocardial Infarction 25%
• Target Lesion 25%
• Low Dose Rate 25%
• Bioengineering 25%
• Long-term Efficacy 25%
• Cardiac Death 25%
• Target Vessel Revascularization 25%
• Native Coronary Artery 25%
• Long-term Safety 25%
• Reintervention 25%
• Drug-eluting Stent 25%
• Major Adverse Events 25%
• Fort 25%
• Restenosis 25%
• Follow-up Rate 25%
• In-stent 25%
• Late Lumen Loss 25%

Medicine and Dentistry

• Rapamycin 100%
• Endothelial Progenitor Cell 100%
• Adverse Event 33%
• Coronary Artery 33%
• Myocardial Infarction 33%
• Stent Thrombosis 33%
• Thrombosis 33%
• Heart Death 33%
• Target Lesion 33%
• Target Vessel Revascularization 33%
• Restenosis 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Rapamycin 100%
• Taxus 100%
• Adverse Event 33%
• Heart Infarction 33%
• Stent Thrombosis 33%
• Heart Death 33%
• Thrombosis 33%
• Restenosis 33%